For those interested in making contributions in Dr. Schrier’s memory:
Select School of Medicine, and under
“Special Instructions/Other Designation”, write, “Stanley Schrier Memorial Fund”.
Alternatively, please make gifts payable to: Stanford University. On the Memo line or an accompanying note, please indicate “Stanley Schrier Memorial Fund”. Please submit your donation to: Development Services, P.O. Box 20466, Stanford, CA 94309-0466
See Below for other publications
Message from the Chief
Welcome to the Stanford Division of Hematology, a dynamic center for basic and translational research, clinical trials, patient care, and teaching. Our physicians, scientists, staff, and trainees collaborate to advance the understanding and treatment of hematologic disorders, all with the goal of improving outcomes for patients with these diseases. In pursuit of this objective, we engage with the broader Stanford community to bring innovation to our efforts.
Over the last 20 years, multiple novel therapies have resulted in significant clinical advances for hematologic diseases, and Stanford investigators have played key roles in their development, including imatinib for CML, ibrutinib for CLL, midostaurin for mast cell disease, and many others. Our clinicians have expertise in a broad range of hematologic disorders including acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, multiple myeloma, amyloidosis, thrombotic diseases, coagulation disorders, and general hematology.
The basic and translational research efforts of the division have led to fundamental discoveries in areas as diverse as leukemia & stem cells, genomics, thrombosis, telomere & cancer biology, and the microbiome. Our passionate faculty members have mentored and trained leaders in the field of hematology and are committed to attract the next generation of leading physicians and research scientists. We invite you to learn more about us through our website.
SHC once again named on U.S. News & World Report's "Best Hospitals" Honor Roll
Stanford Cancer Care jumped from 21st to 12th!
Stanford Health Care (SHC) has once more been named one of the country's top hospitals. Notably, Stanford Health Care achieved national acclaim in Cancer among other areas in the domains of safety, quality of care, patient experience, and patient outcomes. Stanford's Cancer Care had a remarkable jump from 21st to 12th!
Overall, Stanford Hospital's national ranking rose to 12th, ranking 4th in California and 1st in the San Jose metropolitan area. Special thanks to our Hematology and Oncology Physicians and SHC for this remarkable performance!
Dr. Calvin Kuo and Dr. Tian Zhang Featured in the 2021 DoM Annual Report
The Stanford Department of Medicine launched the 2021 Annual Report on May 26, 2021. The report is filled with many interesting stories and articles about what the department has done over the past year. Hematology's own Dr. Tian Zhang and Dr. Calvin Kuo are featured in the report. You can access the report here.
Congratulations to Hematology Fellow, Dr. Ilana Yurkiewicz, on her recent publication with Dr. Steven Coutre
Congratulations to Ilana Yurkiewicz, MD and Steven Coutre, MD, for their publication in Leukemia and Lymphoma. The publication is titled Moxetumomab pasudotox as re-treatment for heavily pretreated relapsed hairy cell leukemia. See the article here.
Resident Research Retreat April 2021 with Dr. Chien and Dr. Mannis
Dr.Caroline Berube Published on ASH Clinical News
You Make the Call: How long should a young patient with COVID-19 and pulmonary embolism receive anticoagulation?
Dr. Caroline Berube, Clinical Assistant Professor in the Division of Hematology at Stanford, published an article with ASH discussing "anticoagulation for a young patient with COVID-19 and pulmonary embolism".
Stanford Hematology ASH 2020: Abstracts
Ravi Majeti Named the RZ Cao Professor
Ravi Majeti, MD, PhD, Chief of the Division of Hematology, was recently named the RZ Cao Professor. He is the inaugural recipient of this professorship, which recognizes his extraordinary leadership in cancer immunotherapy and the basic sciences.
The RZ Cao Professorship was established by an anonymous donor to support basic science professorships in the School of Medicine.
Endowed professorships are the highest honor bestowed in academia. They signify the university’s belief in the faculty member, recognize his or her leadership and vision, and provide ongoing and crucial financial support. This professorship honors Majeti’s tremendous accomplishments, leadership, and dedication to Stanford.
Please join us in congratulating him.
Congratulations, Dr. Tamara Dunn!
Associate Chair of Diversity and Inclusion
The Division of Hematology congratulates Dr. Tamara Dunn for being appointed as the Associate Chair of Diversity and Inclusion in the Department of Medicine. Dr. Dunn has been an active voice for diversity and inclusion for many years. Read more about Dr. Dunn here.
Ravindra Majeti, MD, PhD Awarded Leukemia & Lymphoma Society Grant
The LLS awarded $6.75 million to nine of the most exceptional scientists in the field. Among the awardees was Stanford Hematology's Ravindra Majeti, MD, PhD.
"Dr. Majeti is generating cell-based models to test the progression of preleukemic cells into acute myeloid leukemia (AML). His lab will use these models to test potential therapies and the role of the microenvironment in disease progression".
Read the rest of the story here.
Dr. Tamara Dunn was featured on the CBS morning news on Friday, January 22, 2021 as she was speaking on the importance of getting the COVID-19 vaccine.